Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunological Evaluation of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Given by Particle-mediated Epidermal Delivery (PMED) in Patients With Tumor Type Known to Express NY-ESO-1 or LAGE-1 Antigen.

NCT00199849 is registered in ClinicalTrials.gov with Ludwig Institute for Cancer Research as lead sponsor.

NCT NCT00199849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00199849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunological Evaluation of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Given by Particle-mediated Epidermal Delivery (PMED) in Patients With Tumor Type Known to Express NY-ESO-1 or LAGE-1 Antigen.
Lead sponsor
Ludwig Institute for Cancer Research
Phase
Phase 1
Overall status
Completed
Start date
September 27, 2004
Completion date
September 30, 2007
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, esophageal cancer, non-small cell lung cancer, prostate cancer, sarcoma